Leprosy is a chronic infectious disease caused by Mycobacterium leprae that mainly affects the skin and peripheral nerves. Over recent years, many important advances have been made in developing molecular diagnostics, in identifying highly effective drugs and designing multidrug regimens for treatment, and in unravelling the genomic structure and functions of the leprosy bacillus. Using the new information about specific sequences of M. leprae, several gene probes and gene amplification systems for confirming diagnosis and monitoring treatment have been developed. Among these, polymerase chain reaction (PCR)-based methods have been useful in confirming the diagnosis in paucibacillary leprosy (where few bacilli are present). RNA-targeting systems for monitoring the progress of treatment, in situ hybridisation techniques for analysing specimens with nonspecific histological features, and molecular methods for direct detection of rifampicin/dapsone resistance are other major technological advances with immense applied value. Several effective regimens for the treatment of leprosy have been developed, which include rifampicin, clofazimine and dapsone as core drugs. Although these regimens are generally satisfactory, limitations in terms of persisting activity and late reactions/relapses in paucibacillary leprosy, and persistence of dead and/or live organisms in multibacillary forms of the disease, have been observed.
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The demonstration of the bacterial aetiology of leprosy in 1873 by the Norwegian Armauer Hansen (yielding the alternative names for leprosy of Hansen's disease and Hanseniasis) is considered one of the important landmarks in the arena of infectious diseases. However, because it has not been possible to cultivate Mycobacterium leprae in vitro, progress in understanding the biology of leprosy bacillus has been very slow. The success achieved in growing leprosy bacillus in the mouse foot (Ref. 1) galvanised leprosy research, leading to extensive work in different animal models, development of new chemotherapeutic agents, and the analysis of the biochemical, antigenic and molecular structure of leprosy bacillus. These advances have culminated in important developments in terms of both molecular diagnostics for early diagnosis and effective regimens for the treatment of leprosy. This article briefly reviews the aetiopathology of
Epidemiology
The current geographical distribution of leprosy is shown in Figure 1 . The global burden of the disease has decreased tremendously since the introduction of multidrug treatment (MDT) in 1982. Nearly half a million cases are estimated to remain worldwide, mainly in the Asian and African subcontinents (Table 1) . Countries where leprosy continues to be a major problem include Brazil and India. Although no non-human sources of infection have been established, naturally occurring infection in monkeys and armadillos has been reported. M. leprae-like organisms have also been reported to be present in soil. The mode of transmission of leprosy has not been fully established, but nose and skin are considered as the main portals of exit as well as entry (Ref. 2) .
Clinical features and classification
The incubation period of the disease is long and highly variable (usually 2-10 years). Most individuals exposed to infection are naturally protected, are able to mount an efficient immune response, and do not suffer from the disease. In those who suffer from the disease, the main clinical features in paucibacillary (PB) disease (see below) result from damage due to immune responses mounted by the host, whereas in the lepromatous (LL) forms bacillary load and to some extent immune response are responsible for the clinical presentation. Symptoms and signs pertaining to involvement of the skin and nerves are most commonly encountered, including hypopigmented macules and sensory loss (Ref.
3). At least two of the following findings have to be present for a clinical diagnosis of leprosy: (1) a characteristic patch or skin lesion with impaired sensations; (2) a thickened and/or tender cutaneous or peripheral nerve with impairment of sensations in the area supplied by it; and (3) acid-fast bacteria in the skin smear.
The disease is formally classified into a range of subtypes that include, in approximate order of extent of disease, 'suspicious', early indeterminate (I), tuberculoid (TT), borderline tuberculoid (BT), mid borderline (BB), borderline lepromatous (BL) and LL disease (Ref. 4) . Other forms, such as pure neurotic leprosy (without skin lesions), are also recognised (Ref. 5). The degree and type of immune response and also probably the route of infection determine the clinical forms of the disease. Individuals with strong cell-mediated immunity (CMI) or delayed-type hypersensitivity (DTH) show a localised TT disease, whereas individuals lacking CMI progress from I to LL disease. The immune defect is specific to M. leprae; other immune responses remain intact. The disease is characterised by the formation of granulomas; these vary from epithelioid type in TT leprosy to foamy cell (macrophage) type in LL disease (Ref. 6) .
The lepromin skin test, which measures DTH to M. leprae antigens, is used to assist diagnosis and classification of leprosy (Ref. 7). The response is biphasic, with an early response at 24-48 h, and a late response at 3-4 weeks. Bacterial load in the disease can be estimated from a smear, taken from skin lesions, stained for acid-fast bacteria. Density of bacteria (both viable and nonviable) is expressed using the logarithmic Ridley Scale 
Reactions and relapses
Episodes of acute inflammation in the leprosy lesions and/or in nerves and other body parts have been popularly referred to as 'reactions'. It is hypothesised that these are brought about by disturbances in immunological balance as a result of immune reactivity to M. leprae antigens. Identical antigenic determinants of the host might also contribute to the autoimmune phenomenon. Three types of reactions are recognised. (1) Type I 26 ). These assays have been reported to be sensitive to 1-10 organisms and to be positive in 95-100% of BL/LL and 50-70% of TT, BL and I specimens (Refs 10, 14). rRNAtargeting probes have been developed into in situ hybridisation protocols and have been found to be of value in confirmation of diagnosis in cases with nonspecific histological features (Mohan Natrajan, Central JALMA Institute for Leprosy, Agra, India, pers. commun.). Therefore, in situ hybridisation and immunohistological approaches (Ref. 27) provide good diagnostic strategies to enhance the sensitivity and specificity of histological diagnosis. Forty to fifty per cent of cases missed by standard histology can be confirmed by the use of molecular methods. Absence of positivity in the remaining cases could reflect the need to further optimise these methods, and/or the possibility that many cases with nonspecific histological features might not be leprosy. These probes and gene amplification assays can be of immense help for the diagnosis of early atypical PB leprosy and also in mass confirmation of diagnosis for epidemiological and research purposes (Refs 10, 14).
Molecular methods for monitoring treatment
As M. leprae has not been cultivated in any acceptable in vitro medium system, time- 
Molecular methods for monitoring drug resistance
The lack of a suitable in vitro cultivation system for M. leprae has also hindered assessment of drug resistance. Molecular biology has provided important tools to investigate the molecular mechanisms of drug susceptibility and resistance in leprosy. The use of dapsone and rifampicin as monotherapies to treat leprosy in the 1970s resulted in the rapid emergence of drug resistance. With the introduction of MDT the trend has been apparently reversed and at present drug resistance is not considered a major problem. However, as active surveillance studies have not been carried out, the exact magnitude of drug resistance currently is not known. As in M. tuberculosis, mutations in the M. leprae rpoB locus are associated with rifampicin resistance (Refs 33, 34). The basis of dapsone resistance appears complex, but mutations in the M. leprae folPI locus have been found to be associated with a high degree of dapsone resistance (Ref. 35) . PCR is used to directly amplify the target loci (rpoB for rifampicin and folPI for dapsone) and mutations are confirmed by techniques such as hybridisation with appropriate probes or sequencing. Little is known about the basis of resistance for drugs such as clofazimine. With the use of new techniques for the detection of mutations directly from clinical specimens, surveillance programmes to determine the exact magnitude of drug-resistant mutants to rifampicin, and possibly other drugs, can be undertaken from the biopsies.
Sequencing of the genome of M. leprae has been completed (Ref. 36 ). The information generated opens new opportunities in functional genomics and proteomics. Such studies will undoubtedly provide scope to develop improved molecular methods for confirmation of diagnosis, for assessing prognosis and for detection of drug resistance.
Current therapy for leprosy
There have been rapid changes in the treatment of leprosy in the past few decades. The therapeutic scenario has moved from dapsone monotherapy in the 1970s to MDT using drugs such as dapsone, rifampicin and clofazimine. MDT was expected to shorten the length of treatment, leading to better patient compliance, and reduce the problem of drug resistance because of the combined use of multiple drugs with differing modes of action. MDT has indeed revolutionised the treatment of the disease and has been greatly welcomed by patients and doctors alike. More recently, several newer, more-potent drugs and immunomodulators have been introduced in the treatment of leprosy. This has increased the scope for further improvement in the treatment of the disease.
Evolution and current status of WHO MDT regimens
The World Health Organization (WHO) introduced MDT in 1982, and advocated shortcourse treatment regimens (Ref. 37 ). According to WHO guidelines, PB patients were to be treated Advances in the diagnosis and treatment of leprosy 6 expert reviews in molecular medicine with two drugs [rifampicin (600 mg, once a month, supervised) and dapsone (100 mg, daily, unsupervised, for 6 months)]. As most of these patients are lepromin-positive, it was thought that any residual organisms remaining after stoppage of therapy would be taken care of by the immunity of the host. Treatment for MB patients comprised three drugs [rifampicin (600 mg, once a month, supervised), clofazimine (300 mg, once a month, supervised; along with 50 mg, daily, unsupervised) and dapsone (100 mg, daily, unsupervised)]. The treatment was to be given for 2 years or until the attainment of smear negativity -whichever was earlier.
In the early 1990s, the concept of fixedduration treatment (FDT) was introduced for control programmes. It was advocated that treatment in PB cases should be stopped after completion of six supervised doses taken in a maximum of 9 months, and treatment in MB cases be stopped after completion of 24 supervised doses in 36 months, irrespective of whether the smears were positive or negative (Ref. 38). This duration has been further reduced to 12 months for MB cases, and a single-dose regimen comprising rifampicin (600 mg), ofloxacin (400 mg) and minocycline (100mg) (ROM) has been recommended for mono-lesion cases (Refs 39, 40). These regimens have already been implemented by control programmes in some countries, such as India (Ref. 41) .
Although ROM and 12-month FDT regimens have been introduced only recently, considerable experience has accumulated on the application of various earlier recommended MDT regimens. The overall response has been good. With MDT, there is rapid killing of M. leprae and also faster negativity has been observed from the main portal of exit and dissemination -the nose. Confidence in the results has led to the declaration of 'cured' patients, and thus the prevalence of recorded leprosy cases has declined significantly worldwide. Problems of drug resistance using these regimens also appear to be under control. However, some limitations have been consistently observed, and in order to achieve more-effective patient care and control of the disease it is important to discuss these.
Limitations in PB leprosy therapy
On the whole, treatment in this group of patients appears satisfactory (Ref. 42 ). There are four issues that require debate, as follows. 57) . For example, some bacteria might not be multiplying at the time of administration of the drug and will therefore not be targeted; also, some cases will be MB or progressing towards MB disease, for which this single-dose regimen is absolutely inadequate.
Limitations in MB leprosy therapy
MB patients have a higher bacterial load and, to prevent the emergence of drug-resistant strains, treatment for 2 years or until smear negativity (Ref. 37) was recommended with at least three drugs: rifampicin, clofazimine and dapsone. This regimen has been found to be highly bactericidal and well tolerated, and is widely accepted. With this regimen, the incidence and severity of reactions decreased and the compliance of the patients has improved. Most of the MB patients become smear negative with 24 doses, although the highly bacillated cases require 5-6 years to become smear negative. 
Treatment of MB leprosy with newer or alternative drugs
Several newer drugs active against M. leprae have emerged that are being evaluated to improve the treatment and reduce the duration of treatment in MB leprosy. Prominent among these are: quinolones (pefloxacin, ofloxacin and sparfloxacin, moxifloxacin); ansamycins (rifabutin, KRM-1648); macrolides (clarithromycin); tetracyclines (minocycline), fuscidic acid and other sulphones (brodimoprim). Of these, quinolones, minocyline and clarithromycin appear to be the front runners in providing alternative drug treatment for MB leprosy (Refs 8 expert reviews in molecular medicine these newer drugs are limited. Trials have been conducted in MB patients with an intensive shortcourse regimen consisting of daily treatment with 600 mg rifampicin plus 400 mg of ofloxacin for 1 month. The treatment was then stopped and patients followed-up on placebo (Refs 64, 68) . The initial results suggest that the regimen is well tolerated, but high relapse rates have been observed (Refs 68, 69) . Trials have also been conducted using the addition of supervised monthly doses of 100 mg minocycline plus 400 mg ofloxacin to the standard MB MDT regimen, with the treatment stopped after 1 year (Ref. 70) . The response to the therapy was satisfactory during the treatment and early follow-up period (Ref. 70); however, conclusions can be drawn only after a longer and adequate follow-up.
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Role of immunotherapy in the treatment of leprosy
Besides the presence of a small population of viable organisms ('persisters') after therapy, the problem of persistence of a large pool of dead bacilli is often encountered. Immunomodulators that can stimulate CMI have been applied to reduce this pool. These agents can be divided into three broad groups: drugs, antigenically related mycobacteria, and other immunomodulators (Ref. 71 ).
In the drug category, levamisole (Ref. 
Therapy of reactions
Efficient management of reactions to prevent nerve damage requires good clinical judgment in making an appropriate early diagnosis and assessing the extent of severity in terms of nerve deficit and multi-organ involvement. 
Future challenges
The treatment of leprosy has improved significantly over recent years and this has helped to tackle the disease at the public health level. However, optimal regimens are still evolving. Some of the recently recommended regimens such as single-dose ROM and 12-month FDT need to be kept under close scrutiny for some time, and various modified regimens that have shown promising results need to be considered for improving the therapy. The idea of developing a common regimen for PB and MB leprosy is also gaining momentum (Refs 42, 48, 67) and needs to be pursued. The addition of newer effective drugs such as ofloxacin and minocycline to treatment regimens is increasing, and their potential in effectively reducing the duration of treatment and the management of special situations such as resistance or intolerance is apparent. Many patients require individual attention and tailormade treatment. Indications for such improvisations could be a poor response to standard treatment and hypersensitivity to some of the drugs. For such patients, replacement of the drug(s) might be required (Refs 94, 95) . Currently, several WHO-and ILEP-sponsored trials to monitor various regimens, including some new alternatives, are progressing (Ref. 95) .
As the total patient load has been considerably reduced, easy diagnositc methods such as skin smears for acid-fast bacilli should be reintroduced for monitoring of cases at field-level clinics. Molecular methods should be available at reference laboratories and be more extensively used in research and epidemiological studies.
Leprosy has been a feared disease mainly because of the deformities associated with it. After widespread use of MDT, there has been a sea change in the profile of the disease. Early and appropriate treatment undoubtedly helps in reducing the severity and frequency of deformities. Nevertheless, disabilities continue to be a major problem (Ref. 96) . Different preventive (management of reactions, nerve decompression) and corrective (tendon transfers, management of plantar ulcers) procedures to manage deformities are available. Besides the availability of surgery, timely physiotherapy and health education are very important in the prevention, management and rehabilitation resulting from the disabilities. As leprosy patients continue to have disabilities for a long time or even life, these services will be required for a much longer time.
Genuine concerns have been raised about the continued high-incidence rates of leprosy even in areas with intensive MDT campaigns for 10-15 years. The issues of inadequate coverage, nonhuman sources, extraordinarily long incubation periods and effectiveness of regimens being used need to be analysed for these unexpected results. The rich experience of the past of treating leprosy patients with different regimens, together with lessons from careful follow-up of new regimens and the appropriate use of molecular tools for early diagnosis and surveillance of drug resistance, provide an excellent base from which to progress towards the goals of sensitive and specific diagnostics as well as optimal regimens expert reviews in molecular medicine for all leprosy patients. The knowledge emanating from analysis of the human genome and the M. leprae and M. tuberculosis genomes (Ref. 97) will undoubtedly strengthen the development of relevant technologies for more-effective management of leprosy at patient and public health levels. expert reviews in molecular medicine
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Further reading, resources and contacts
The WHO's Action Programme for the Elimination of Leprosy provides current information on therapy, endemic countries, research and publications.
http://www.who.int/lep/ LEPRA is a UK-based medical development charity whose prime objective is to eradicate leprosy.
http://www.lepra.org.uk/
The Novartis Foundation for Sustainable Development 'has been actively involved in leprosy programs in Asia, Africa and Latin America in partnership with local health authorities, the WHO and nongovernmental agencies'. The efforts of the foundation focus primarily on eliminating leprosy, and their website is a useful source of information on the diagnosis, treatment and elimination of the disease.
http://www.novartisfoundation.com/leprosy/index.htm
Leproma is a powerful web-based tool for extracting information on gene structure and function from a Mycobacterium leprae genome database, using programmes such as BLAST and FASTA.
http://genolist.pasteur.fr/Leproma
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